Hycells New Product | Anti-Payload—MMAE/MMAF/DXD Antibody
Release Date:
2024-04-30 14:10
Product Background Overview
Antibody-drug conjugates (ADCs) are an emerging class of targeted therapies for cancer treatment, designed to deliver Small-molecule chemical drugs (Payload) is directly delivered to and kills tumor cells; ADCs are essentially targeted chemotherapeutic agents that have now advanced to the third generation, with significantly improved safety and efficacy, and further technological innovations are increasingly focused on In areas such as the payload, linker, and conjugation technologies, the modification and optimization of the payload have consistently been a key focus in ADC development.
The second-generation payloads are primarily tubulin inhibitors. These agents disrupt mitosis; since tumor cells divide more rapidly than most normal cells, tubulin inhibitors are particularly effective at killing cancer cells. Tubulin inhibitors can be classified into two types: one type promotes tubulin polymerization, leading to uncontrolled microtubule growth, such as MMAE and MMAF, derivatives of tetrodotoxin ; the 14 approved ADC drug Among them, six ADC drugs use tetrodotoxin-derived payloads, accounting for nearly 50% of the total; moreover, more than 80 pipeline projects currently under development employ MMAE as the payload, making tetrodotoxin derivatives the most commonly used payload to date. Another class of agents that effectively inhibits microtubule assembly and induces mitotic arrest in cells includes, for example, Meidengsu Derivatives such as DM1 and DM4.
Third-generation payload DNA inhibitors can disrupt DNA structure and function through mechanisms such as double-strand breaks, alkylation, intercalation, cross-linking, and inhibition of topoisomerase I (TOPO1), thereby promoting cancer cell death. DNA inhibitors are further classified into DNA-damaging agents and topoisomerase I inhibitors. DNA-damaging agents include calicheamicins, PBD (Pyrrolo[3,2-b]benzodiazepine) derivatives, bleomycin derivatives, and others. Topoisomerase I inhibitors are primarily camptothecin derivatives, including irinotecan, SN38, and DXD. Topoisomerase I facilitates the completion of DNA Topological structure Its expression level is significantly higher in tumor cells than in normal cells; topoisomerase I inhibitors induce cell death by trapping the topoisomerase I–DNA cleavage complex.
To support ADC pharmacokinetic analysis, Hycells Bio has launched several anti-payload antibodies; Hycells’ Anti-Payload antibodies feature High specificity, high stability, and high sensitivity These characteristics can be leveraged for plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug-binding affinity, DAR value analysis, and evaluation of ADC efficacy, thereby accelerating the ADC drug development process and providing a basis for preclinical application and dose optimization.
Anti-Payload Antibody Verification Data Display
DXD Antibody Data Validation
★ High Purity: Verified by SDS-PAGE, purity greater than 90%.
DXD antibody on SDS-PAGE under reducing (R) conditions. The protein purity is greater than 90%.
★ High affinity: Can bind DXD with high affinity
Binding Activity of ADC-1(DXD) with Anti-DXD Antibody: Assessed by its binding capacity in a functional ELISA. Immobilized ADC-1(DXD) at 1 μg/mL binds the anti-DXD antibody, with an EC50 of 2.298–10 ng/mL.
★ DXD Monoclonal Antibody PK Application Assay Demonstration
MMAE and MMAF antibody data validation
★ MMAE Monoclonal Antibody Binding Activity Assay
For more details on Hycells Bio’s payload antibodies, please contact our sales representative. Scan the QR code below to request a free trial sample.
Contact: Mr. Xie 15201775322 。
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board